VRTX

Vertex Pharmaceuticals
Biotechnology · Health Care · as of 2026-11-20
Last close
$522.41
+0.3% on the session
1-year return
+24.1%
+20.2% over six months
Volatility
29.5%
annualized, trailing year
Max drawdown
-15.2%
worst peak to trough, 1y
What the numbers say

Vertex Pharmaceuticals is a biotechnology name in the health care sector. Over the past year it returned +24.1%, against -4.6% over three months and -2.4% over one. It trades 7.7% above its 200-day average, so the longer trend is confirming recent strength. Annualized volatility of 29.5% is moderate by single-stock standards.

Its worst peak-to-trough decline over the year was -15.2%, and it has traded a median $593M a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate 0.21 with the S&P 500 proxy, so it has been moving substantially on its own.

Where it ranks
Within Health Care#35 of 59
Stronger than 41% of its sector on the momentum profile
Across the whole index#165 of 497

How VRTX scores on all four profiles

Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 7 others in Biotechnology.

Start a free 7-day trial
Full metrics
1 day+0.3%
1 week-3.0%
1 month-2.4%
3 months-4.6%
6 months+20.2%
1 year+24.1%
12-1 momentum+27.1%
Volatility (1y, annualized)29.5%
Max drawdown (1y)-15.2%
Distance vs 200-day average+7.7%
Return per unit of risk0.82
Median daily dollar volume$593M
Free newsletter

Get VRTX when it shows up in a ranking

Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.

Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.